Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5095932 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| 3 | EXPERIMENTAL | - |
| 4 | PLACEBO_COMPARATOR | - |
| 1active | EXPERIMENTAL | - |
| 1placebo | PLACEBO_COMPARATOR | - |
| 2active | EXPERIMENTAL | - |
| 2placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Subcutenaous once weekly for 4 weeks |
| RO5095932 | DRUG | Escalating subcutaneous doses once weekly over a 4 weeks period |
| metformin | DRUG | stable dose |
Inclusion Criteria: * Adult patients, 18-65 years of age * Diabetes mellitus, type 2 for at least 6 months before screening * On treatment with stable doses of metformin for at least 3 months before screening * BMI between \>/=25 and \</=39 Exclusion Criteria: * Type 1 diabetes * Pancreatitis * T...
RO5095932 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities. The drug is being studied in patients with Type 2 diabetes, including those on stable metformin therapy.
RO5095932 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes Mellitus. As of now, the drug is in Phase 1 development and has not received regulatory approval.
RO5095932 is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total of 154 participants enrolled. The drug is investigational and has not been approved by the FDA or any other regulatory body. It is being studied for the treatment of Type 2 Diabetes Mellitus.
RO5095932 has been studied in two completed Phase 1 clinical trials: NCT00961909, which enrolled 122 patients with Type 2 Diabetes Mellitus, and NCT01017302, which enrolled 32 patients with Type 2 diabetes on stable metformin therapy. Both trials were conducted in the United States and were randomized, double-blind, and placebo-controlled.
RO5095932 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Type 2 Diabetes Mellitus. Two Phase 1 trials have been completed, but the drug has not yet progressed to later stages of development or received marketing authorization. It remains under investigation for safety and efficacy.